Dr Tahir Sultan Shamsi, who introduced bone marrow transplant treatment for Leukemia in Pakistan, passed away at a private hospital in Karachi on Tuesday.
Survivors include two sons, three daughters and a widow. His funeral prayers were offered at Najam Mosque on Tipu Sultan Road. The funeral prayer was attended by thousands of people belonging to different schools of thought, including political leaders while a large number of people belonging to the medical field including Pakistan Islamic Medical Association, Pakistan Medical Association and Pakistan Pharmaceutical were also present.
After the funeral prayers in the afternoon, Dr Tahir Shamsi was buried in the graveyard at Yousufpura RCD Road. Funeral prayers were attended by Jamaat-e-Islami Karachi Amir Hafiz Naeem-ur-Rehman, Head of Indus Hospital Prof. Abdul Bari Khan, Dr Saqib Ansari, Prof. Rafiq Khanani, Abdullah Feroze and thousands of other citizens.
After the funeral prayer, Hafiz Naeem-ur-Rehman said that Dr Tahir Shamsi was a symbol of service. The federal government should grant him a national award in recognition of his services.
Read More: Mother Child Hospital to be operational in Feb
Head of Indus Hospital Dr Abdul Bari Khan said that Dr Tahir Shamsi has formed such a team which will carry forward his mission.
Dr Tahir Shamsi was born on February 18, 1962. He was blessed to memorize the Holy Quran at the young age of eight years. Dr Tahir Shamsi secured his MBBS from Dow Medical College Karachi in 1988 and obtained post-graduate degree from UK for blood diseases including blood cancer. He graduated from the Royal College of Pathologists.
Dr Tahir Shamsi has more than 43 research publications in international journals while he has also written seven books. He was also the editor of several haematology journals. His articles on blood diseases are also included in the medical curriculum of India.
Published in The Express Tribune, December 22nd, 2021.
COMMENTS (1)
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ